In vivo pharmacology of the new angiotensin II receptor antagonist KRH-594

被引：0
|
作者：
Murakami, M
Inada, Y
Tazawa, S
Wang, JX
Nakao, K
机构：
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 1998年 / 358卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P3842
引用
收藏
页码：R275 / R275
页数：1
相关论文
共 50 条
  • [1] Pharmacology of KRH-594, a novel highly potent nonpeptide angiotensin II receptor antagonist.
    Tamura, K
    Okuhira, M
    Amano, H
    Inokuma, K
    Hashimoto, K
    Mikoshiba, I
    FASEB JOURNAL, 1997, 11 (03): : 214 - 214
  • [2] Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II receptor antagonist
    Tamura, K
    Okuhira, M
    Amano, H
    Inokuma, K
    Hirata, T
    Mikoshiba, I
    Hashimoto, K
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 30 (05) : 607 - 615
  • [3] In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist
    Tamura, K
    Okuhira, M
    Mikoshiba, I
    Hashimoto, K
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 1997, 20 (08) : 850 - 855
  • [4] Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension
    Inada, Y
    Murakami, M
    Kaido, K
    Nakao, K
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1999, 49 (01): : 13 - 21
  • [5] Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors
    Inada, Y
    Nakane, T
    Chiba, S
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2002, 16 (04) : 317 - 323
  • [6] KRH-594, a new angiotensin AT1 receptor antagonist, ameliorates nephropathy and hyperlipidaemia in diabetic spontaneously hypertensive rats
    Inada, Y
    Murakami, M
    Tazawa, S
    Akahane, M
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2000, 27 (04): : 270 - 276
  • [7] KRH-594, a new angiotensin AT1 receptor antagonist, prevents end-organ damage in stroke-prone spontaneously hypertensive/Izm rats
    Inada, Y
    Tazawa, S
    Murakami, M
    Akahane, M
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2001, 28 (03) : 206 - 211
  • [8] IN-VIVO PHARMACOLOGY OF SC-51316, A NONPEPTIDIC ANGIOTENSIN-II RECEPTOR ANTAGONIST
    OLINS, GM
    SMITS, GJ
    KOEPKE, JP
    HUANG, HC
    REITZ, DB
    MANNING, RE
    BLAINE, EH
    AMERICAN JOURNAL OF HYPERTENSION, 1993, 6 (07) : 619 - 625
  • [9] In vivo pharmacology of an angiotensin AT(1) receptor antagonist with balanced affinity for angiotensin AT(2) receptors
    Kivlighn, SD
    Zingaro, GJ
    Gabel, RA
    Broten, TP
    Chang, RSL
    Ondeyka, DL
    Mantlo, NB
    Gibson, RE
    Greenlee, WJ
    Siegl, PKS
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 294 (2-3) : 439 - 450
  • [10] Overview of the clinical pharmacology of eprosartan, a novel angiotensin II receptor antagonist
    Ilson, B
    JOURNAL OF HYPERTENSION, 1998, 16 : S234 - S234
12345